This week, we take a "full breath" and dive into the Canadian cannabis sector, exploring two tech-focused companies that perfectly embody the industry's highs and lows.

Jon Brown looks at MediPharm Labs (TSX: LABS), a company successfully expanding its pharmaceutical-grade products globally, yet simultaneously embroiled in a public proxy battle with a dissident shareholder, forcing investors to weigh innovation against internal conflict. Then, Trevor Abes highlights Cannabix Technologies (CSE: BLO), a company diligently developing a first-of-its-kind marijuana breathalyzer, securing key partnerships and seeing its stock rise—all before booking its first dollar of revenue.

This Episode's Picks:

MediPharm Labs Corp. (TSX: LABS): A pharmaceutical cannabis company expanding its metered-dose inhalers to Europe while fighting a proxy battle that raises questions about governance and stability.

Cannabix Technologies Inc. (CSE: BLO): A pre-revenue technology pioneer that has achieved key testing milestones and a major manufacturing deal for its cannabis and alcohol breathalyzer.

Topics Discussed:

• The cannabis technology and pharmaceutical sectors.


• Shareholder activism and proxy battles.


• Balancing operational momentum with corporate governance risks.


• Investing in pre-revenue, development-stage technology companies.


• The market for cannabis breathalyzer and impairment detection technology.

Further Reading & Resources:

• What is going on with MediPharm Labs?


• Diversify away from cannabis retail with this technology stock


• Cannabix Technologies Enters Contract Manufacturing Agreement with Price Industries for BreathLogix Devices


• This week’s picks: TSX:LABS | CSE:BLO

Follow The Podcast:

• Follow on Podbean


• Follow on Spotify


• Follow on Apple Podcasts

Disclaimer: The material provided in this podcast is for information only and should not be treated as investment advice. For full disclaimer information, please visit themarketonline.ca/disclaimer.